Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 22;7(1):1-8.
doi: 10.1093/jcag/gwad023. eCollection 2024 Feb.

Choosing Therapy for Moderate to Severe Crohn's Disease

Malcolm Irani  1 , Bincy Abraham  1
Affiliations

Choosing Therapy for Moderate to Severe Crohn's Disease

Malcolm Irani et al. J Can Assoc Gastroenterol. .

Abstract

The availability of approved therapies for Crohn's disease has significantly increased over the past decade. To choose the appropriate therapy for the patient, ideally head to head studies, and data on positioning could help the provider individualize the decision. Due to the paucity of head-to-head trial data, we turn to network meta-analysis and real-world studies to help guide our treatment choices. Ultimately, the best approach is to consider each patient on an individual basis, taking into consideration the characteristics of their disease, individual risk factors, extra-intestinal manifestations, co-morbid conditions, patient age, cost, and personal preferences. In this review, we summarize the evidence comparing biologic as well as small molecule therapies for the treatment of moderate-to-severe Crohn's disease. We have summarized the evidence in relation to factors such as efficacy, fistulizing disease, pregnancy, infection risk, and co-existing conditions.

Keywords: Crohn’s disease; choosing; moderate; severe; therapy.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Turner, D, Ricciuto A, Lewis A, D’Amico F, Dhaliwal J, Griffiths AM, Bettenworth D,. et al.; International Organization for the Study of IBD. “STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.” Gastroenterology 160, no. 5 (2021): 1570–83. doi: 10.1053/j.gastro.2020.12.031. - DOI - PubMed
    1. Hommes, DW. “Step-Up Versus Top-Down Therapy in the Treatment of Crohn’s Disease.” Gastroenterology & Hepatology 2, no. 8 (2006): 546–7. - PMC - PubMed
    1. Ungaro, RC, Aggarwal S, Topaloglu O, Lee W-J, Clark R, and Colombel JF.. ”Systematic Review and Meta-Analysis: Efficacy and Safety of Early Biologic Treatment in Adult and Paediatric Patients With Crohn’s Disease”. Alimentary Pharmacology & Therapeutics 51, no. 9 (2020): 831–42. doi:10.1111/apt.15685. - DOI - PMC - PubMed
    1. Rubin, DT, Uluscu O, and Sederman R.. ” Response to Biologic Therapy in Crohn’s Disease is Improved With Early Treatment: An Analysis of Health Claims Data”. Inflammatory Bowel Disease 18, no. 12 (2012): 2225–31. doi:10.1002/ibd.22925. - DOI - PubMed
    1. Kane, S, Huo D, Aikens J, and Hanauer S.. “Medication Nonadherence and the Outcomes of Patients With Quiescent Ulcerative Colitis”. The American Journal of Medicine 114, no. 1 (2003): 39–43. doi:10.1016/s0002-9343(02)01383-9. - DOI - PubMed

LinkOut - more resources